Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zymeworks (NYSE:ZYME – Get Rating) will be releasing its earnings data after the market closes on Tuesday, March 7th. Analysts expect Zymeworks to post earnings of $4.62 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Zymeworks Price Performance ZYME opened at […]
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following t...
Antibody-drug conjugates (ADCs) represent a significant advance in therapeutic engineering. They combine an antibody, a linker, and a payload...
Mid-cap stocks have a market capitalization between $2 billion to $10 billion, and these firms are considered to have established operations and increasing profits.
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities...